LY294002 IS A PROMISING INHIBITOR TO OVERCOME SORAFENIB RESISTANCE IN FLT3-ITD MUTANT AML CELLS BY INTERFERING WITH PI3K/AKT SIGNALING PATHWAY

LY294002 Is a Promising Inhibitor to Overcome Sorafenib Resistance in FLT3-ITD Mutant AML Cells by Interfering With PI3K/Akt Signaling Pathway

Internal tandem duplications (ITD) mutation within FMS-like tyrosine kinase 3 (FLT3), the most frequent mutation happens in almost 20% acute myeloid leukemia (AML) patients, always predicts a poor prognosis.As a small molecule tyrosine kinase inhibitor, sorafenib is clinically used for the treatment of advanced renal cell carcinoma (RCC), hepatocel

read more

Neuromorphic atomic switch networks.

Efforts to emulate the formidable information processing capabilities of the brain through neuromorphic engineering have been bolstered by recent progress in the fabrication of nonlinear, nanoscale circuit elements that exhibit synapse-like operational Projection Screen characteristics.However, conventional fabrication techniques are unable to effi

read more